Core Insights - Citius Oncology will participate in the USCLC Annual Workshop 2026 to discuss LYMPHIR™ and engage with experts in cutaneous T-cell lymphoma (CTCL) treatment [1][4][5] Group 1: Event Details - The USCLC Annual Workshop 2026 will take place on March 26, 2026, at the Hyatt Regency Denver, focusing on advancements in cutaneous lymphoma [1][2] - The workshop will feature small-group discussions among leading dermatologists, hematologist-oncologists, and researchers, fostering direct interaction and exchange of insights [3][6] Group 2: Company Engagement - Citius Oncology's team aims to engage with clinicians and researchers to discuss the treatment landscape for CTCL and share clinical experiences with LYMPHIR™ [4][5] - The participation reflects the company's commitment to collaborating with leading experts in CTCL care to improve patient outcomes [5] Group 3: Product Information - LYMPHIR™ (denileukin diftitox-cxdl) is a targeted immune therapy for relapsed or refractory CTCL, approved for use in Stage I-III disease after at least one prior systemic therapy [9][13] - The initial market for LYMPHIR is estimated to exceed $400 million, indicating significant growth potential in an underserved market [11]

Core Insights - Citius Oncology announced positive topline results from a Phase 1 clinical trial of LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers, indicating potential for enhanced efficacy of immune checkpoint inhibitors [1][2] - The study showed a 24% objective response rate (ORR) and a 48% clinical benefit rate (CBR) among evaluable patients, suggesting promising anti-tumor activity [1] Company Overview - Citius Oncology is focused on developing and commercializing novel targeted oncology therapies, with LYMPHIR being a key product approved for treating relapsed or refractory cutaneous T-cell lymphoma [1][2] - The company has robust intellectual property protections, including orphan drug designation and pending patents for immuno-oncology applications, which strengthen its competitive position in the market [2] Clinical Study Details - The Phase 1 study was led by the University of Pittsburgh and involved 25 evaluable patients, with no unexpected safety signals reported [1] - LYMPHIR was administered intravenously in escalating doses alongside pembrolizumab, with the aim of establishing a recommended dose for future studies [1] Market Potential - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies, indicating significant growth potential [2] - The combination therapy approach with LYMPHIR and pembrolizumab may address the unmet needs in treating recurrent or metastatic gynecologic cancers, which have limited treatment options [1][2]

Core Insights - Citius Oncology announced positive topline results from a Phase 1 trial of LYMPHIR (E7777) showing an 86% overall response rate in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [1] - The trial demonstrated effective Treg depletion and promising efficacy signals, with no dose-limiting toxicities observed [1][2] - LYMPHIR is FDA-approved for treating relapsed or refractory cutaneous T-cell lymphoma and is being investigated for its potential to enhance CAR-T therapy efficacy [1][2] Company Overview - Citius Oncology, Inc. is focused on developing and commercializing novel targeted oncology therapies, with LYMPHIR launched in December 2025 for treating adults with relapsed or refractory Stage I-III cutaneous T-cell lymphoma [2] - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [2] - Citius has robust intellectual property protections, including orphan drug designation and pending patents for immuno-oncology use [2] Study Design and Results - The Phase 1 trial was an open-label, dose-escalation study involving 14 patients with poor prognostic features, who received LYMPHIR followed by standard commercial CD19-directed CAR-T therapy [1] - Key findings included a median reduction of 24 Tregs/µL and a favorable safety profile, with all patients completing treatment and proceeding to CAR-T infusion [1][2] - The study's design aimed to augment lymphodepletion prior to CAR-T infusion, potentially improving antitumor activity [1] Treatment Context - DLBCL accounts for approximately 30%-40% of newly diagnosed non-Hodgkin lymphoma cases in the U.S., with high-risk features associated with poor outcomes [1] - Novel strategies like transient regulatory T-cell depletion are being explored to improve treatment efficacy in this challenging patient population [1]

Market Overview - Investor focus is shifting beyond mega-cap stocks, with earnings revisions improving across various sectors, including small caps, which may unlock value dislocations accumulated over the last three years [1] - For small-cap outperformance to continue, consistent upward earnings revisions and a compression of the valuation spread between small and large caps are necessary [1] Portfolio Positioning - Interest is growing in mid-caps, small-caps, international stocks, and investment-grade fixed income, moving away from a primary focus on US mega-caps [2] - Concerns exist regarding market concentration in mega-cap tech companies and potential disappointments in that sector [2] - The next phase of AI-related trades may involve small and mid-cap companies leveraging AI products for productivity gains, as these firms are more labor-intensive and may have greater earnings leverage if AI enhances productivity [2] Citius Oncology Inc. (NASDAQ:CTOR) - Citius Oncology has entered an exclusive distribution agreement with Uniphar to expand its oncology treatment, LYMPHIR, in Europe, marking its third major international agreement [7] - LYMPHIR is currently FDA-approved in the US but lacks commercial marketing authorization in Europe, limiting its availability to specific patient groups under local legal frameworks [8] - The drug targets patients with Stage I-III cutaneous T-cell lymphoma, functioning as a recombinant fusion protein to selectively destroy cancerous T-cells [9][10] Ceragon Networks Ltd. (NASDAQ:CRNT) - Ceragon Networks reported Q4 2025 revenue of $82.3 million, a 23% decline from Q4 2024, with full-year revenue totaling $338.7 million, down 14.1% year-over-year [11] - Management is optimistic for 2026, projecting revenue guidance of $355 to $385 million, driven by the launch of new products and a multimillion-dollar private network contract in the Asia-Pacific region [12] - The company is diversifying revenue streams through private networks in mining and energy sectors while managing supply chain costs by qualifying secondary sources [13][14]

Financial Performance - Citius Oncology reported $3.9 million in revenue for the fiscal first quarter 2026, marking its first reported revenue following the launch of LYMPHIR in December 2025[1][7]. - The net loss for the quarter was $5.5 million, or $(0.06) per share, compared to a net loss of $6.7 million, or $(0.09) per share, for the prior-year period[7][14]. - The net loss for 2025 was $5,534,069, an improvement from a net loss of $6,659,205 in 2024[16]. - Stock-based compensation expense increased to $3,956,050 in 2025 from $1,808,478 in 2024[16]. - Net cash used in operating activities was $(7,354,946) for 2025, with significant changes in accounts receivable and inventory[16]. - License payments for investing activities amounted to $(4,400,000) in 2025[16]. - Net proceeds from the issuance of common stock were $15,125,489, contributing positively to financing activities[16]. - The net change in cash and cash equivalents for 2025 was an increase of $3,370,543[16]. - Cash and cash equivalents at the end of the period reached $7,295,451, up from $3,924,908 at the beginning[16]. - Interest paid during the period was $14,460[16]. Expenses - Research and development expenses decreased to $1.0 million from $1.3 million in the prior-year period, reflecting reduced clinical development activity[7][14]. - General and administrative expenses were $2.9 million, down from $3.3 million in the prior-year period[7][14]. Market Opportunity - The initial market for LYMPHIR is estimated to exceed $400 million and is growing, indicating a significant opportunity in an underserved market[6][7]. - Citius Oncology is advancing an international access strategy through regional distribution partners and Named Patient Programs in key European and Middle Eastern markets[7][4]. - The company is focused on expanding its field presence to support a concentrated prescriber base in the rare cancer setting, utilizing an AI-enabled commercial platform[2][7]. Strategic Focus - Citius Oncology is evaluating strategic opportunities to enhance long-term shareholder value while maintaining capital management[3][7]. - The company established a nationwide specialty distribution infrastructure to ensure immediate product availability and support rapid physician adoption of LYMPHIR[4][7].

Core Viewpoint - Citius Pharmaceuticals, Inc. has reported its first revenue of $3.9 million following the launch of LYMPHIR, marking a significant milestone in its transition to a revenue-generating company [1]. Business Highlights - The company successfully launched LYMPHIR in December 2025, generating initial sales through a nationwide network of distributors [1]. - Citius Pharma anticipates growth opportunities through early signals from investigator-initiated studies and potential international market expansion [1]. - The company is focused on advancing its late-stage pipeline, which includes Mino-Lok and Halo-Lido, while maintaining financial stewardship [1]. Financial Highlights - For the fiscal first quarter ended December 31, 2025, Citius reported a net loss of $8.2 million, or $(0.41) per share, an improvement from a net loss of $9.8 million, or $(1.30) per share, in the prior-year period [1]. - Stock-based compensation expenses increased to $4.3 million from $2.5 million year-over-year, while general and administrative expenses rose slightly to $5.7 million [1]. - Research and development expenses decreased to $1.6 million from $2.1 million, reflecting reduced clinical development activity [1]. Cash Flow and Financing - The company generated net proceeds of approximately $20.9 million from equity financings during the quarter [1]. - Cash and cash equivalents totaled $7.7 million as of December 31, 2025, compared to $4.3 million at the end of the previous quarter [1]. Market Potential - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [1]. - Citius Oncology's robust intellectual property protections, including orphan drug designation and pending patents, support its competitive positioning in the oncology market [1].

Core Viewpoint - Citius Oncology, Inc. has successfully launched LYMPHIR, generating $3.9 million in revenue for the first fiscal quarter of 2026, marking a significant transition from a development-stage organization to a commercial oncology company [1]. Business Highlights and Subsequent Developments - The company is focused on accelerating physician adoption and expanding patient access to LYMPHIR, with initial distributor sales completed nationwide [1]. - Citius Oncology is preparing to expand its field presence to support a concentrated prescriber base in the rare cancer setting, utilizing an AI-enabled commercial platform for market penetration [1]. - The company is exploring strategic opportunities to enhance long-term shareholder value while managing capital effectively [1]. Financial Highlights for First Quarter 2026 - The net loss for the quarter was $5.5 million, or $(0.06) per share, an improvement from a net loss of $6.7 million, or $(0.09) per share, in the prior-year period [1]. - Stock-based compensation expense increased to $4.0 million, primarily due to equity grants, compared to $1.8 million in the previous year [1]. - General and administrative expenses decreased to $2.9 million from $3.3 million, while research and development expenses were reduced to $1.0 million from $1.3 million [1]. - The company completed a registered offering in December 2025, generating net proceeds of approximately $15.1 million, and reported cash and cash equivalents of $7.3 million as of December 31, 2025 [1]. Market Opportunity - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [1]. - Citius Oncology holds robust intellectual property protections, including orphan drug designation and pending patents for immuno-oncology use, which support its competitive positioning [1].

Core Insights - Citius Oncology has entered into an exclusive distribution agreement with Uniphar to expand access to LYMPHIR in Europe, marking its third international distribution partnership [1][2] - The agreement allows Uniphar to manage access and distribution of LYMPHIR in specific territories in Western and Eastern Europe through country-specific managed access programs [1] - LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) and is not yet approved for commercial use outside the United States [1][2] Company Overview - Citius Oncology, a subsidiary of Citius Pharmaceuticals, focuses on developing and commercializing novel targeted oncology therapies [2] - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [2] - Citius Oncology has robust intellectual property protections, including orphan drug designation and pending patents for immuno-oncology use [2] Product Information - LYMPHIR (denileukin diftitox-cxdl) is indicated for use in Stage I-III CTCL after at least one prior systemic therapy [1] - The drug works by binding to IL-2 receptors on cancer cells, leading to cell death through inhibition of protein synthesis [1] - In 2021, denileukin diftitox received regulatory approval in Japan for treating relapsed or refractory CTCL and peripheral T-cell lymphoma [1] Distribution Partner - Uniphar is an international healthcare services company that supports over 200 pharmaceutical and medical technology manufacturers [2] - The partnership with Citius Oncology aims to improve patient outcomes for those with relapsed or refractory CTCL [1][2] - Uniphar operates across 180 countries and integrates various services to support the full product lifecycle from research to commercialization [2]

Core Viewpoint - Purcell & Lefkowitz LLP is investigating Citius Oncology, Inc. to determine if its directors breached fiduciary duties related to recent corporate actions [1] Group 1 - The investigation is on behalf of Citius Oncology's shareholders [1] - Shareholders interested in more information about their rights and options are encouraged to visit the law firm's website or contact them directly [1] - The law firm specializes in representing shareholders affected by securities fraud and corporate misconduct [2]

Product Launch and Market Potential - Citius Oncology launched LYMPHIR™, a novel immunotherapy, in the U.S. in December 2025 for treating adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy[3] - The initial market for LYMPHIR is estimated to exceed $400 million, indicating significant growth potential in an underserved market[5] - Citius Oncology secured access to LYMPHIR in 19 international markets through regional distribution partners via Named Patient Programs, marking a step in its global access strategy[6] - The company executed service agreements with three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR to healthcare organizations across the U.S.[3] - Citius Oncology announced a collaboration with Verix to enhance commercial targeting and provider engagement for LYMPHIR's U.S. commercialization[6] Financial Performance - The net loss for the fiscal year ended September 30, 2025, was $24.8 million, or ($0.34) per share, compared to a net loss of $21.1 million, or ($0.31) per share, in 2024[6] - Net loss for 2025 was $(24,761,369), compared to $(21,148,747) in 2024, indicating a worsening financial position[16] - Cash and cash equivalents stood at $3.9 million as of September 30, 2025, compared to $112 in 2024[11] - Stock-based compensation expense increased to $8,320,419 in 2025 from $7,498,817 in 2024, reflecting higher employee compensation costs[16] - Inventory changes resulted in a significant increase of $(12,649,207) in 2025, compared to $(2,133,871) in 2024, indicating potential overstock issues[16] Cash Flow and Financing Activities - Net cash used in operating activities was $(5,492,046) in 2025, a decline from a positive cash flow of $126,353 in 2024[16] - Net cash provided by financing activities rose to $15,166,842 in 2025, up from $4,873,759 in 2024, showing increased capital raising efforts[16] - Cash and cash equivalents at the end of 2025 were $3,924,908, a significant increase from $112 at the beginning of the year[16] - License payments for 2025 amounted to $(5,750,000), consistent with $(5,000,000) in 2024, indicating ongoing investment in licenses[16] - Interest paid in 2025 was $187,389, while no interest was reported in 2024, suggesting new debt obligations[16] Expenses Overview - Research and development expenses increased to $6.4 million for the fiscal year ended September 30, 2025, up from $4.9 million in 2024[6] - General and administrative expenses rose to $8.8 million for the fiscal year ended September 30, 2025, compared to $8.1 million in 2024[6] - The company reported a capital contribution of due to related party by parent of $33,180,961 in 2024, which was not repeated in 2025[16] - Net prepaid manufacturing transferred to inventory was $1,368,720 in 2025, down from $6,134,895 in 2024, indicating a shift in production strategy[16]